8-K: Soleno Therapeutics Appoints Biopharma Veteran Mark Hahn to Board

Soleno Therapeutics strengthens its Board and Audit Committee with the appointment of Mark W. Hahn, a seasoned biopharmaceutical finance executive, to support the commercial launch of VYKAT XR.

Summary

• Soleno Therapeutics, Inc. increased the size of its Board of Directors and Audit Committee by one member.
• Mark W. Hahn was appointed to the Board and Audit Committee, effective October 13, 2025, to serve as a Class II director with a term expiring at the 2028 annual meeting of stockholders.
• Mr. Hahn brings nearly 30 years of CFO-level experience in the life sciences sector, including key roles in numerous successful product launches, financings, and M&A transactions.
• His prior experience includes serving as CFO of Verona Pharma PLC until its acquisition by Merck & Co., Inc. for approximately $10 billion in October 2025.
• He also served as CFO of Dova Pharmaceuticals until its acquisition by Swedish Orphan Biovitrum (Sobi) for up to $915 million in November 2019, where he was instrumental in raising capital and launching its first rare disease product.
• From 2010 to 2017, Mr. Hahn was CFO of Cempra, Inc., leading its IPO and several subsequent follow-on offerings.
• The company believes Mr. Hahn's background perfectly aligns with its current needs, particularly for the commercial launch of VYKAT XR.
• In connection with his appointment, Mr. Hahn received a grant of 10,046 restricted stock units (RSUs), with one-third vesting annually starting October 13, 2026.
• He will participate in the compensation program applicable to all non-employee directors and executed the company's standard indemnification agreement.
• With Mr. Hahn's addition, the Soleno Board now consists of seven members.

Sentiment

Score: 8

Explanation: The appointment of a highly experienced biopharmaceutical finance executive with a proven track record in product launches, financings, and M&A, particularly for a company entering commercialization, is a significant positive development that strengthens the Board and enhances strategic capabilities.

Positives

• The appointment of Mark W. Hahn, a highly experienced biopharmaceutical finance executive, significantly strengthens the Board and Audit Committee.
• Mr. Hahn's nearly 30 years of CFO-level experience includes a proven track record in successful product launches, capital raises, and M&A transactions within the life sciences sector.
• His background is directly relevant to Soleno's current strategic focus on the commercial launch of VYKAT XR for Prader-Willi syndrome.
• Mr. Hahn's past successes include involvement in Verona Pharma PLC's acquisition by Merck & Co., Inc. for approximately $10 billion and Dova Pharmaceuticals' acquisition by Swedish Orphan Biovitrum (Sobi) for up to $915 million.
• The addition of an independent director with such extensive expertise enhances corporate governance and financial oversight.

Risks

• Forward-looking statements are subject to a number of risks, uncertainties, and assumptions, and actual results could differ materially from those projected.

Future Outlook

The company is focused on the continued strong commercial launch of VYKAT XR, its first approved product for Prader-Willi syndrome, and aims to maximize its reach to the PWS community.

Management Comments

• "I am very pleased to welcome Mark to the Soleno Board as we continue to execute a strong commercial launch of VYKAT XR." Dr. Anish Bhatnagar, Chief Executive Officer and Chairman of the Board of Soleno Therapeutics.
• "With his broad and diverse financial leadership experience, including as CFO of commercial-stage companies developing therapeutics for rare and serious diseases, I believe Marks background perfectly aligns with our current needs, and I look forward to his contributions." Dr. Anish Bhatnagar.
• "Having seen first-hand the positive impact that innovation can have on the lives of people living with rare diseases, I could not be more excited to join the Soleno Board at this stage in the Company’s evolution as a commercial organization." Mark W. Hahn.
• "I look forward to working with Anish, my fellow Board members, and the Soleno leadership team to maximize the reach of VYKAT XR and offer new hope to the PWS community, including patients, their physicians and caregivers." Mark W. Hahn.

Industry Context

The biopharmaceutical industry, particularly the rare disease segment, is characterized by high R&D costs, complex regulatory pathways, and significant commercialization challenges. Successful product launches and strategic M&A activities are critical for growth and shareholder value. Soleno's focus on the commercial launch of VYKAT XR for Prader-Willi syndrome positions it within this specialized market, where expertise in finance, product launch, and strategic transactions, as brought by Mr. Hahn, is highly valued.

Comparison to Industry Standards

• Mr. Hahn's experience with Verona Pharma PLC, which was acquired by Merck & Co., Inc. for approximately $10 billion, demonstrates his involvement in high-value strategic transactions, comparable to significant M&A events in the biopharmaceutical sector.
• His role in Dova Pharmaceuticals, acquired by Swedish Orphan Biovitrum (Sobi) for up to $915 million, highlights his expertise in navigating successful exits for rare disease companies, a key benchmark for investor returns in this specialized market.
• Leading Cempra, Inc.'s IPO and subsequent follow-on offerings aligns with standard capital raising strategies for emerging biopharma companies seeking to fund clinical development and commercialization.
• The appointment of a director with extensive financial and commercialization experience is a common practice for biopharmaceutical companies transitioning to a commercial stage, aiming to enhance governance and strategic execution.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to strengthened corporate governance and the addition of an experienced executive whose background aligns with successful product launches, financings, and M&A, potentially enhancing long-term value.
• Management/Employees: Benefits from enhanced strategic guidance and financial expertise on the Board, supporting the commercialization efforts of VYKAT XR.
• Patients/Caregivers (PWS Community): Positive impact as the appointment aims to maximize the reach of VYKAT XR, offering new hope for the treatment of hyperphagia in Prader-Willi syndrome.

Next Steps

• Continue the strong commercial launch of VYKAT XR.
• Maximize the reach of VYKAT XR to the Prader-Willi syndrome (PWS) community.
• Mr. Hahn will serve on the Board until the annual meeting of stockholders in 2028.
• One-third of Mr. Hahn's RSUs will vest annually starting October 13, 2026.

Key Dates

Recommendation

The appointment of Mark W. Hahn, a highly accomplished biopharmaceutical finance executive with a proven track record in successful product launches, capital raises, and M&A transactions, significantly strengthens Soleno Therapeutics' Board and Audit Committee. His expertise is directly aligned with the company's critical phase of commercially launching VYKAT XR for Prader-Willi syndrome. This strategic enhancement to leadership is a strong positive signal for investors, indicating a commitment to robust financial management and successful commercial execution, which could drive future growth and shareholder value.

Keywords

Biopharmaceutical, Rare Diseases, Prader-Willi Syndrome, VYKAT XR, Board Appointment, CFO, Audit Committee, Corporate Governance, Life Sciences, Commercial Launch